ClinicalTrials.gov
ClinicalTrials.gov Menu

International BPA Registry

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03245268
Recruitment Status : Recruiting
First Posted : August 10, 2017
Last Update Posted : October 30, 2018
Sponsor:
Information provided by (Responsible Party):
International CTEPH Association

Brief Summary:
The International Balloon Pulmonary Angioplasty (BPA) Registry is a prospective, multi-center, long-term observational project. Scheduled to start data collection in Q4 2017, the registry will run for approximately four years with a follow-up time for each patient of at least two years. Its primary objective is to investigate the efficacy and safety of BPA intervention in patients with chronic thromboembolic pulmonary hypertension (CTEPH) not amenable to pulmonary endarterectomy (PEA).

Condition or disease Intervention/treatment
Chronic Thromboembolic Pulmonary Hypertension CTEPH Procedure: Balloon pulmonary angioplasty

Study Type : Observational [Patient Registry]
Estimated Enrollment : 500 participants
Observational Model: Cohort
Time Perspective: Prospective
Target Follow-Up Duration: 2 Years
Official Title: International BPA Registry
Actual Study Start Date : March 2, 2018
Estimated Primary Completion Date : March 2, 2022
Estimated Study Completion Date : March 2, 2022



Intervention Details:
  • Procedure: Balloon pulmonary angioplasty
    BPA is an interventional technique where a balloon catheter is used to recanalize affected segments of pulmonary arteries identified during angiography.
    Other Name: BPA


Primary Outcome Measures :
  1. Safety as assessed by BPA-associated complications [ Time Frame: Min. 2 years ]
  2. Efficacy as assessed by change in PVR [ Time Frame: Min. 2 years ]
    Change in pulmonary vascular resistance (PVR) from baseline to latest post-interventional follow-up hemodynamics

  3. Efficacy as assessed by change in mPAP [ Time Frame: Min. 2 years ]
    Change in mean pulmonary arterial pressure (mPAP) from baseline to latest post-interventional follow-up hemodynamics


Secondary Outcome Measures :
  1. Compare volume of BPA cases across regions and case load at the end of recruitment [ Time Frame: Min. 2 years ]
  2. Analyze patient selection criteria for BPA across sites at the end of recruitment [ Time Frame: Min. 2 years ]
  3. At the end of follow-up, compare technical aspects of BPA as asssed by imaging modalities as used by the sites [ Time Frame: Min. 2 years ]
    Imaging modalities encompass VQ scan, selective pulmonary angiogram, CT pulmonary angiogram, dual-energy CT, cone-beam CT, MRI, OCT and IVUS

  4. At the end of follow-up, compare technical aspects of BPA as assessed by investigator-reported session goals [ Time Frame: Min. 2 years ]
  5. At the end of follow-up, compare technical aspects of BPA as assessed by number of sessions per patient and follow-up [ Time Frame: Min. 2 years ]
  6. At the end of follow-up, compare technical aspects of BPA as assessed by number of interventions per patient and follow-up [ Time Frame: Min. 2 years ]
  7. At the end of follow-up, compare technical aspects of BPA as assessed by technical limits [ Time Frame: Min. 2 years ]
  8. Analyze the use of PH targeted medical therapy before BPA [ Time Frame: Min. 2 years ]
    PH targeted therapy will be categorised as prostacyclin, IP agonist, PDE5 inhibitor, ERA, guanylate cyclase stimulator and other

  9. Analyze the use of PH targeted medical therapy after BPA [ Time Frame: Min. 2 years ]
    PH targeted therapy will be categorised as prostacyclin, IP agonist, PDE5 inhibitor, ERA, guanylate cyclase stimulator and other

  10. Analyze the impact of PH targeted medical treatment on key patient outcomes [ Time Frame: Min. 2 years ]
    PH targeted therapy will be categorised as prostacyclin, IP agonist, PDE5 inhibitor, ERA, guanylate cyclase stimulator and other Key patient outcomes encompass WHO functional class, 6-minute-walk-distance, Borg dyspnoe score, haemodynamics and mortality

  11. Health care resource use required to complete BPA [ Time Frame: Min. 2 years ]
    As assessed by total hospital days in/out



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients diagnosed with CTEPH meeting the inclusion criteria listed below and scheduled to undergo BPA intervention are eligible for inclusion into the International BPA Registry.
Criteria

Inclusion Criteria:

  • Diagnosis with CTEPH according to the following criteria:

    • Mean PAP ≥ 25mmHg at rest; or if mean PAP < 25mmHg at rest, have exercise limitations from chronic thromboembolic disease
    • Abnormal ventilation perfusion lung scanning (VQ) scan, pulmonary angiogram, computer tomographic pulmonary angiogram, or magnetic resonance pulmonary angiogram confirming chronic thromboembolic disease as recommended by standard guidelines
  • Treatment with anticoagulation for ≥ 3 months before diagnosis of CTEPH
  • Naïve to BPA treatment
  • Scheduled to undergo their first BPA session ≥ 1 day after enrollment. Enrollment is defined as date the consent is signed by the patient. Enrollment must occur before any BPA session
  • Willing to provide informed consent

Exclusion Criteria:

  • BPA treatment prior to enrollment
  • Pulmonary hypertension cause other than World Health Organization (WHO) group IV (CTEPH)
  • Targeted BPA treatment lesion other than from WHO group IV (CTEPH)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03245268


Contacts
Contact: Fabrizio Canonaco, Dr + 41 41 379 79 70 fabrizio.canonaco@cteph-association.org
Contact: Simone Lerch, Dr + 41 41 379 79 70 simone.lerch@cteph-association.org

Locations
United States, California
University of California San Diego Recruiting
La Jolla, California, United States, 92093
Contact: Nick H Kim, Prof       h33kim@ucsd.edu   
Contact: Michael M Madani, Prof       mmadani@ucsd.edu   
United States, Massachusetts
Massachusetts General Hospital Recruiting
Boston, Massachusetts, United States, 02114
Contact: Alison S Witkin, Dr         
United States, Minnesota
Mayo Clinic Recruiting
Rochester, Minnesota, United States, 55905
Contact: Robert Frantz, Prof         
United States, Ohio
Cleveland Clinic Recruiting
Cleveland, Ohio, United States, 44195
Contact: Gustavo Heresi, Dr         
Austria
University Clinics Recruiting
Vienna, Austria
Contact: Irene M Lang, Prof       irene.lang@meduniwien.ac.at   
Belgium
Universitaire Ziekenhuizen Leuven Recruiting
Leuven, Belgium
Contact: Laurent Godinas, Dr         
Contact: Marion Delcroix, Prof       marion.delcroix@uzleuven.be   
Czechia
General University Hospital Recruiting
Prague, Czechia
Contact: Pavel Jansa, Dr         
France
Centre Hospitalier Universitaire Grenoble-Alpes Recruiting
Grenoble, France
Contact: Hélène Bouvaist, Dr         
L'Hôpital Marie Lannelongue Recruiting
Le Plessis-Robinson, France
Contact: Philippe Brenot, Prof         
Germany
Kerckhoff-Klinik GmbH Recruiting
Bad Nauheim, Germany
Contact: Eckhard Mayer, Prof       E.Mayer@kerckhoff-klinik.de   
Japan
National Hospital Organization Okayama Medical Center Recruiting
Okayama, Japan
Contact: Hiromi Matsubara, Prof       matsubara.hiromi@gmail.com   
National Cerebral and Cardiovascular Center Recruiting
Osaka, Japan
Contact: Takeshi Ogo, Prof         
Keio University Hospital Recruiting
Tokyo, Japan
Contact: Takashi Kawakami, Prof         
Kyorin University Hospital Recruiting
Tokyo, Japan
Contact: Toru Satoh, Prof         
Netherlands
VU Medical Center Recruiting
Amsterdam, Netherlands
Contact: Anton Vonk Noordegraaf, Prof         
Poland
European Health Center Otwock LLC Recruiting
Warsaw, Poland
Contact: Marcin Kurzyna, Prof         
United Kingdom
Papworth Hospital Recruiting
Cambridge, United Kingdom
Contact: Joanna Pepke-Zaba, Prof       joanna.pepke-zaba@nhs.net   
Contact: David Jenkins, Dr       david.jenkins1@nhs.net   
Sponsors and Collaborators
International CTEPH Association
Investigators
Principal Investigator: Nick H Kim, Prof International CTEPH Association

Additional Information:
Responsible Party: International CTEPH Association
ClinicalTrials.gov Identifier: NCT03245268     History of Changes
Other Study ID Numbers: BPA Registry
First Posted: August 10, 2017    Key Record Dates
Last Update Posted: October 30, 2018
Last Verified: October 2018

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by International CTEPH Association:
Balloon pulmonary angioplasty
BPA

Additional relevant MeSH terms:
Hypertension, Pulmonary
Lung Diseases
Respiratory Tract Diseases